SCHEMBL1968657

SCHEMBL1968657

CCc1cc2c(N3CCc4c([nH]n(-c5ccccc5)c4=O)C3)nc(Cl)nc2s1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 2/20 0.40
ATM Q13315 1/20 0.39
P2RY12 Q9H244 5/20 0.38
HTR6 P50406 1/20 0.38
KDM4E B2RXH2 2/20 0.37
RAB9A P51151 2/20 0.37
TMIGD3 P0DMS9 1/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968096 0.86 HTR6 (0.46) SMN1; SMN2TSHRHTTMEN1KMT2A
SCHEMBL1966413 0.85 P2RY12 (0.49) SMN1; SMN2TP53MAPTTSHRHTT
SCHEMBL1969208 0.82 ALDH1A1 (0.42) SMN1; SMN2TSHRHTTMEN1KMT2A
SCHEMBL12409637 0.79 GBA1 (0.45) MEN1KMT2AATMHTR6KDM4E
SCHEMBL1970586 0.76 HTR6 (0.49) SMN1; SMN2TP53MAPTTSHRHTT
SCHEMBL1972065 0.71 HTR6 (0.46) SMN1; SMN2TP53MAPTTSHRHTT
SCHEMBL1966749 0.71 P2RY12 (0.43) SMN1; SMN2TP53MAPTTSHRHTT
SCHEMBL1969007 0.71 P2RY12 (0.46) SMN1; SMN2MAPTHTTMEN1KMT2A
SCHEMBL1967052 0.70 HTR6 (0.47) SMN1; SMN2TP53MAPTTSHRHTT
SCHEMBL1974318 0.70 HTR6 (0.40) SMN1; SMN2TP53MAPTTSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 SMN1; SMN2 4439/4885TP53 3391/4885MAPT 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.